Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
0.7113
-0.0371 (-4.96%)
At close: Nov 20, 2026, 4:00 PM EST
0.7300
+0.0187 (2.63%)
After-hours: Nov 20, 2026, 7:53 PM EST
Company Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States.
The company’s lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer’s disease, as well as in open-label phase 3 to treat parkinson’s disease.
It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer’s disease and dementia.
Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Annovis Bio, Inc.
| Country | United States |
| Founded | 2008 |
| IPO Date | Jan 29, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Maria Maccecchini |
Contact Details
Address: 101 Lindenwood Drive, Suite 225 Malvern, Pennsylvania 19355 United States | |
| Phone | 484 875 3192 |
| Website | annovisbio.com |
Stock Details
| Ticker Symbol | ANVS |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 1477845 |
| CUSIP Number | 03615A108 |
| ISIN Number | US03615A1088 |
| Employer ID | 26-2540421 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Maria L. Maccecchini Ph.D. | Founder, Acting Chief Financial Officer, Chief Executive Officer, President and Executive Director |
| Dr. Cheng Fang Ph.D. | Chief Scientific Officer |
| Eve M. Damiano M.S., RAC | Senior Vice President of Regulatory Operations |
| Blake Jensen M.B.A. | Head of Quality |
| Hilda Maibach | Senior Vice President of Statistics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2026 | 10-Q | Quarterly Report |
| Nov 13, 2026 | 8-K | Current Report |
| Nov 5, 2026 | 8-K | Current Report |
| Nov 5, 2026 | 424B5 | Filing |
| Nov 4, 2026 | 424B5 | Filing |
| Nov 4, 2026 | 8-K | Current Report |
| Nov 4, 2026 | 8-K | Current Report |
| Oct 30, 2026 | 8-K | Current Report |
| Oct 20, 2026 | 8-K | Current Report |
| Oct 15, 2026 | SCHEDULE 13G/A | Filing |
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides